Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics is a Texas biotech developing PIKTOR, an experimental cancer drug that blocks several points in a growth pathway. It last closed at $9.04 on Nov 17, down 2.59% on the day. The average 12-month price target from 4 analysts is $61.00 (+574.8% from the last close), with a high of $69.00 and a low of $56.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $957K, the largest $642K.
Key Stats
Last 12 monthsNot reported for this period.
From FTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on FTH in the past 90 days. The average target is $61.00, with a high of $69.00 and a low of $56.00, compared with the last close of $9.04.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Citigroup | Maintained | Buy | $60 |
| Nov 4 | Guggenheim | Maintained | Buy | $69 |
| Sep 16 | Guggenheim | Initiated | Buy | $70 |
| Sep 14 | LUCID CAPITAL MARKETS | Initiated | Buy | $59 |
| Aug 21 | Needham | Initiated | Buy | $56 |
Technical Analysis
The stock is 82% below its 20 day and 164% below its 50 day average. It is 181% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $9.03, and the nearest resistance the Pivot R1 at $9.48.
| RSI (14) | 24.72 | Oversold below 30 | Oversold |
| MACD | -3.75 | Below its signal line | Bearish |
| Stochastic | 2.3 | Near the bottom of its range | Oversold |
| ADX (14) | 33.3 | Trending down | |
| Williams %R | -96.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -139.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −54.0% | Change over 10 sessions | Bearish |
| ATR (14) | $2.37 | Typical daily range, 26.2% of price |
| RSI (14) | 36.06 | Weak, oversold below 30 | Neutral |
| MACD | -2.56 | Below its signal line | Bearish |
| Stochastic | 7.9 | Near the bottom of its range | Oversold |
| ADX (14) | 25.6 | Trending down | |
| Williams %R | -98.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -187.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −75.8% | Change over 10 sessions | Bearish |
| ATR (14) | $6.39 | Typical daily range, 70.7% of price |
What happened before
See how FTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How FTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in FTH in the last 90 days.
Dark Pool
30DFTH Institutional Ownership
Full report →- ▲63 buying vs 15 selling
- ▲Held by funds +21.5 pts
- ▲Funds holding +34
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 79 | 45 | +75.6% |
| In funds' top 10 | 2 | 1 | +100.0% |
| Held by funds | 75.9% | 54.5% | +21.5 pts |
| New / increased | 41 / 22 | 22 / 17 | +61.5% |
| Reduced / sold out | 8 / 7 | 2 / 7 | +66.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FTH is in one of them and how their past FTH trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered FTH in an article yet. Here's the latest on the wider market.
About Faeth Therapeutics
Faeth Therapeutics is a biotechnology company based in Austin, Texas, that develops cancer treatments. Its lead candidate, PIKTOR, is an oral combination of two drugs designed to block several points in a cell signaling pathway that drives the growth of many solid tumors. PIKTOR is being studied in endometrial cancer and breast cancer, and the company's products are still in clinical trials. The company aims its work at patients with these cancers, based on the idea that blocking more than one point in the pathway may work better than blocking a single point.
- Headquarters
- Austin, TX


